Peter Soon-Shiong
MD
Founder and Chief Executive Officer
👥Biography 个人简介
Peter Soon-Shiong leads ImmunityBio, which developed the IL-15 superagonist N-803 (Anktiva) that gained approval for BCG unresponsive non muscle invasive bladder cancer in combination with BCG. He champions NK cell and IL-15 based strategies across multiple cancer indications. He directs a broad immunotherapy platform and clinical portfolio.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Peter Soon-Shiong 的研究动态
Follow Peter Soon-Shiong's research updates
留下邮箱，当我们发布与 Peter Soon-Shiong（ImmunityBio）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment